

PRODUCT INFORMATION



HAP-1 (trifluoroacetate salt)

Item No. 45762

Formal Name: L-seryl-L-phenylalanyl-L-histidyl-L-glutamyl-L-phenylalanyl-L-alanyl-L-arginyl-L-alanyl-L-threonyl-L-leucyl-L-alanyl-L-serine, trifluoroacetate salt

Peptide Sequence: SFHQFARATLAS-OH

MF: $C_{60}H_{90}N_{18}O_{17} \cdot XCF_3COOH$


FW: 1,335.5

Purity: $\geq 95\%$

Supplied as: A solid

Storage: $-20^{\circ}C$

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

HAP-1 (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the HAP-1 (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. HAP-1 (trifluoroacetate salt) is soluble (≥ 10 mg/ml) in DMSO.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of HAP-1 (trifluoroacetate salt) can be prepared by directly dissolving the solid in aqueous buffers. HAP-1 (trifluoroacetate salt) is sparingly soluble (1-10 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

HAP-1 is a synovial fibroblast-targeting peptide.¹ It has been conjugated to the antimicrobial peptide (KLAK)₂ to generate a pro-apoptotic peptide, which decreases synovial leukocyte infiltration in a rabbit model of rheumatoid arthritis when administered intra-articularly. HAP-1 has also been conjugated to liposomes for the selective delivery of an NF- κ B inhibitory peptide to inflamed synovium in a rat model of rheumatoid arthritis.²

References

1. Mi, Z., Lu, X., Mai, J.C., *et al.* Identification of Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium. *Mol. Ther.* **8**(2), 295-305 (2003).
2. You, C., Zu, J., Liu, X., *et al.* Synovial fibroblast-targeting liposomes encapsulating an NF- κ B-blocking peptide ameliorates zymosan-induced synovial inflammation. *J. Cell. Mol. Med.* **22**(4), 2449-2457 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/25/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM